Evidence map›Paper›PMID 26818520›Full record

ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience2016

Platelet-Activating Factor Receptors Mediate Excitatory Postsynaptic Hippocampal Injury in Experimental Autoimmune Encephalomyelitis.

Matthew J Bellizzi, Jasmine S Geathers, Kevin C Allan, Harris A Gelbard

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Matthew J BellizziCenter for Neural Development and Disease and Department of Neurology (Neuroimmunology Division), University of Rochester Medical Center, Rochester, New York 14642, Matthew_Bellizzi@urmc.rochester.edu.ORCID http://orcid.org/0000-0001-6103-2442
Jasmine S GeathersCenter for Neural Development and Disease, University of Rochester Medical Center, Rochester, New York 14642, and.ORCID http://orcid.org/0000-0002-5201-7854
Kevin C AllanCenter for Neural Development and Disease, University of Rochester Medical Center, Rochester, New York 14642, and.ORCID http://orcid.org/0000-0002-4206-9781
Harris A GelbardCenter for Neural Development and Disease, Departments of Neurology (Child Neurology Division), Pediatrics, and Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York 14642.ORCID http://orcid.org/0000-0001-5095-7976
University of Rochester Medical Center · US

Funding

EXPERIMENTAL THERAPEUTICS IN NEUROLOGICAL DISEASET32NS007338 · NINDS · UNIVERSITY OF ROCHESTER · PI ROBERT G. HOLLOWAY, Michael P McDermott · 1990 to 2026
$6.4M
ROLE OF PAF IN HIV-1 NEUROPATHOGENESISR01MH056838 · NIMH · UNIVERSITY OF ROCHESTER · PI GELBARD, HARRIS A · 1996 to 2014
$5.2M
NIMH NIH HHS R01 MH056838NIMH NIH HHS R01 MH56838NINDS NIH HHS T32 NS007338
6 · The paper itself

Abstract

Gray matter degeneration contributes to progressive disability in multiple sclerosis (MS) and can occur out of proportion to measures of white matter disease. Although white matter pathology, including demyelination and axon injury, can lead to secondary gray matter changes, we hypothesized that neurons can undergo direct excitatory injury within the gray matter independent of these. We tested this using a model of experimental autoimmune encephalomyelitis (EAE) with hippocampal degeneration in C57BL/6 mice, in which immunofluorescent staining showed a 28% loss of PSD95-positive excitatory postsynaptic puncta in hippocampal area CA1 compared with sham-immunized controls, despite preservation of myelin and VGLUT1-positive excitatory axon terminals. Loss of postsynaptic structures was accompanied by appearance of PSD95-positive debris that colocalized with the processes of activated microglia at 25 d after immunization, and clearance of debris was followed by persistently reduced synaptic density at 55 d. In vitro, addition of activated BV2 microglial cells to hippocampal cultures increased neuronal vulnerability to excitotoxic dendritic damage following a burst of synaptic activity in a manner dependent on platelet-activating factor receptor (PAFR) signaling. In vivo treatment with PAFR antagonist BN52021 prevented PSD95-positive synapse loss in hippocampi of mice with EAE but did not affect development of EAE or local microglial activation. These results demonstrate that postsynaptic structures can be a primary target of injury within the gray matter in autoimmune neuroinflammatory disease, and suggest that this may occur via PAFR-mediated modulation of activity-dependent synaptic physiology downstream of microglial activation. SIGNIFICANCE STATEMENT: Unraveling gray matter degeneration is critical for developing treatments for progressive disability and cognitive impairment in multiple sclerosis (MS). In a mouse model of MS, we show that neurons can undergo injury at their synaptic connections within the gray matter, independent of the white matter pathology, demyelination, and axon injury that have been the focus of most current and emerging treatments. Damage to excitatory synapses in the hippocampus occurs in association with activated microglia, which can promote excitotoxic injury via activation of receptors for platelet-activating factor, a proinflammatory signaling molecule elevated in the brain in MS. Platelet-activating factor receptor blockade protected synapses in the mouse model, identifying a potential target for neuroprotective treatments in MS.

Indexed as

AnimalsCalcium-Binding ProteinsCell Line, TumorChromosome PairingCoculture TechniquesDisease Models, AnimalDisks Large Homolog 4 ProteinEncephalomyelitis, Autoimmune, ExperimentalFemaleFibrinolytic AgentsGinkgolidesGray MatterGuanylate KinasesHippocampusLactonesMaleAif1 protein, mouseCalcium-Binding ProteinsDisks Large Homolog 4 ProteinDlg4 protein, mouseFibrinolytic Agentsginkgolide BGinkgolidesGuanylate KinasesLactonesMembrane ProteinsMicrofilament ProteinsMyelin-Oligodendrocyte Glycoproteinmyelin oligodendrocyte glycoprotein (35-55)Peptide Fragmentsplatelet activating factor receptorPlatelet Membrane GlycoproteinsReceptors, G-Protein-CoupledSlc17a7 protein, mouseVesicular Glutamate Transport Protein 1excitotoxicitymicrogliamultiple sclerosisneurodegenerationneuroprotectionplatelet-activating factor

Identifiers

PMID26818520
PMCPMC4728729
OpenAlexW2258144468

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.